Dexmedetomidine administration is associated with a reduced risk of ICU mortality in critically ill patients with ischemic stroke
BackgroundAlthough the administration of dexmedetomidine (DEX) in intensive care unit (ICU) is rapidly increasing, its potential impact on critically ill patients with ischemic stroke has not yet been explored.MethodsPatient data were extracted from the Medical Information Mart for Intensive Care IV...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1571957/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240682506485760 |
|---|---|
| author | Shuiyun Chen Shujiang Ren Xing Li Kewei Liu |
| author_facet | Shuiyun Chen Shujiang Ren Xing Li Kewei Liu |
| author_sort | Shuiyun Chen |
| collection | DOAJ |
| description | BackgroundAlthough the administration of dexmedetomidine (DEX) in intensive care unit (ICU) is rapidly increasing, its potential impact on critically ill patients with ischemic stroke has not yet been explored.MethodsPatient data were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV 3.0) database to identify patients who received DEX and those who did not. The primary outcome was ICU mortality. Statistical analyses included multivariate Cox proportional hazards regression, propensity score matching (PSM), and inverse probability of treatment weighting (IPTW) to ensure the robustness of the findings.ResultsThis study included 646 patients (22.8%) with ischemic stroke who received DEX treatment, and 2,182 patients who did not receive DEX in the ICU. A significant reduction in ICU mortality was observed in the DEX group compared to the non-DEX group, with an adjusted hazard ratio (HR) of 0.52 [95% confidence interval (CI) 0.40–0.68, p < 0.001]. Within the matched cohort, DEX administration did not show a statistically significant increased risk of bradycardia and improvement in 90-day mortality outcomes.ConclusionThese findings suggest that DEX administration may reduce ICU mortality in patients with IS. |
| format | Article |
| id | doaj-art-2e4c5310efb9485792eee657d04325f9 |
| institution | Kabale University |
| issn | 1664-2295 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj-art-2e4c5310efb9485792eee657d04325f92025-08-20T04:00:28ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-08-011610.3389/fneur.2025.15719571571957Dexmedetomidine administration is associated with a reduced risk of ICU mortality in critically ill patients with ischemic strokeShuiyun Chen0Shujiang Ren1Xing Li2Kewei Liu3Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Neurology, Chongqing Medical University, Chongqing, ChinaDepartment of Interventional Medicine, Guangzhou First People’s Hospital, Second Affiliated Hospital of South China University of Technology, Guangzhou, ChinaDepartment of Interventional Medicine, Guangzhou First People’s Hospital, Second Affiliated Hospital of South China University of Technology, Guangzhou, ChinaBackgroundAlthough the administration of dexmedetomidine (DEX) in intensive care unit (ICU) is rapidly increasing, its potential impact on critically ill patients with ischemic stroke has not yet been explored.MethodsPatient data were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV 3.0) database to identify patients who received DEX and those who did not. The primary outcome was ICU mortality. Statistical analyses included multivariate Cox proportional hazards regression, propensity score matching (PSM), and inverse probability of treatment weighting (IPTW) to ensure the robustness of the findings.ResultsThis study included 646 patients (22.8%) with ischemic stroke who received DEX treatment, and 2,182 patients who did not receive DEX in the ICU. A significant reduction in ICU mortality was observed in the DEX group compared to the non-DEX group, with an adjusted hazard ratio (HR) of 0.52 [95% confidence interval (CI) 0.40–0.68, p < 0.001]. Within the matched cohort, DEX administration did not show a statistically significant increased risk of bradycardia and improvement in 90-day mortality outcomes.ConclusionThese findings suggest that DEX administration may reduce ICU mortality in patients with IS.https://www.frontiersin.org/articles/10.3389/fneur.2025.1571957/fullischemic strokedexmedetomidineintensive care unitmortalitysedative |
| spellingShingle | Shuiyun Chen Shujiang Ren Xing Li Kewei Liu Dexmedetomidine administration is associated with a reduced risk of ICU mortality in critically ill patients with ischemic stroke Frontiers in Neurology ischemic stroke dexmedetomidine intensive care unit mortality sedative |
| title | Dexmedetomidine administration is associated with a reduced risk of ICU mortality in critically ill patients with ischemic stroke |
| title_full | Dexmedetomidine administration is associated with a reduced risk of ICU mortality in critically ill patients with ischemic stroke |
| title_fullStr | Dexmedetomidine administration is associated with a reduced risk of ICU mortality in critically ill patients with ischemic stroke |
| title_full_unstemmed | Dexmedetomidine administration is associated with a reduced risk of ICU mortality in critically ill patients with ischemic stroke |
| title_short | Dexmedetomidine administration is associated with a reduced risk of ICU mortality in critically ill patients with ischemic stroke |
| title_sort | dexmedetomidine administration is associated with a reduced risk of icu mortality in critically ill patients with ischemic stroke |
| topic | ischemic stroke dexmedetomidine intensive care unit mortality sedative |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2025.1571957/full |
| work_keys_str_mv | AT shuiyunchen dexmedetomidineadministrationisassociatedwithareducedriskoficumortalityincriticallyillpatientswithischemicstroke AT shujiangren dexmedetomidineadministrationisassociatedwithareducedriskoficumortalityincriticallyillpatientswithischemicstroke AT xingli dexmedetomidineadministrationisassociatedwithareducedriskoficumortalityincriticallyillpatientswithischemicstroke AT keweiliu dexmedetomidineadministrationisassociatedwithareducedriskoficumortalityincriticallyillpatientswithischemicstroke |